. Author manuscript; available in PMC: 2021 Jul 1.

Published in final edited form as: JACC Cardiovasc Imaging. 2019 Oct 11;13(7):1577–1590. doi: 10.1016/j.jcmg.2019.09.006

Table 2:

Suggested future studies for symptomatic MVD without obstructive CAD

• Comparison of all noninvasive methods of MBF quantification to screen for patients with symptomatic MVD in the absence of CAD

• Comparison of CMR versus PET in MVD screening using invasive methods as a gold standard

• Randomized controlled trials assessing the prognostic and symptomatic impact of various pharmacological treatment strategies on symptomatic MVD defined by reduced MPR

• Randomized controlled trials assessing the impact of lifestyle changes including diet, exercise, and smoking cessation on symptomatic MVD defined by reduced MPR

• Assess if specific therapeutic interventions improve quantifiable MPR and determine if any correlation exists with improvement in symptoms, prognosis, or quality of life

• Examine improvements in microcirculation relative to prognosis and symptoms in HFpEF